Radiotherapy‐assisted tumor selective metronomic oral chemotherapy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Cancer

• Publication date

  2017-06-20

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1002/ijc.30842PMID 28635011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor.

  2016cited by this paper
• Induced phenotype targeted therapy: radiation-induced apoptosis-targeted chemotherapy.

  2015cited by this paper
• Optimization of a Stable Linker Involved DEVD Peptide-Doxorubicin Conjugate That Is Activated upon Radiation-Induced Caspase-3-Mediated Apoptosis.

  2015cited by this paper
• Absorption Mechanism of a Physical Complex of Monomeric Insulin and Deoxycholyl-l-lysyl-methylester in the Small Intestine.

  2015cited by this paper
• When less is more: maintenance therapy in colorectal cancer

  2015cited by this paper
• Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.

  2014cited by this paper
• Metronomics: towards personalized chemotherapy?

  2014cited by this paper
• Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats

  2013cited by this paper
• Impact of radiation therapy on survival in patients with triple-negative breast cancer

  2013cited by this paper
• Enhanced oral absorption of ibandronate via complex formation with bile acid derivative.

  2013cited by this paper
• Oral Delivery of Ionic Complex of Ceftriaxone with Bile Acid Derivative in Non-human Primates

  2013cited by this paper
• Molecularly targeted therapies for metastatic triple-negative breast cancer

  2013cited by this paper
• The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

  2013cited by this paper
• Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

  2012cited by this paper
• Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

  2012cited by this paper
• Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

  2012cited by this paper
• Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

  2011cited by this paper
• Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?

  2011cited by this paper
• Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

  2010cited by this paper
• Diabetes correction in pancreatectomized canines by orally absorbable insulin-deoxycholate complex.

  2010cited by this paper
• A change of strategy in the war on cancer

  2009cited by this paper
• Development of Stably Transfected Monolayer Overexpressing the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT)

  2005cited by this paper
• A new drug carrier, Nα-deoxycholyl-l-lysyl-methylester, for enhancing insulin absorption in the intestine

  2005cited by this paper
• Current status of dose-dense chemotherapy for breast cancer

  2005cited by this paper
• A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

  2004cited by this paper
• Intestinal bile acid transport: biology, physiology, and pathophysiology.

  2001cited by this paper
• Chemotherapeutic drugs—more really is not better

  2000cited by this paper
• The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.

  1998cited by this paper
• Active and passive bile acid absorption in man. Perfusion studies of the ileum and jejunum.

  1974cited by this paper
• Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat.

  1972cited by this paper

• Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy

  2024cites this paper
• Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.

  2022cites this paper
• Feedback amplification of senolysis using caspase-3-cleavable peptide-doxorubicin conjugate and 2DG.

  2022cites this paper
• Stimulus-cleavable chemistry in the field of controlled drug delivery.

  2021cites this paper
• Metronomic therapy in pediatric oncology: A snapshot

  2019cites this paper
• Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer.

  2019cites this paper
• The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell‐binding moiety to caspase‐3 activated doxorubicin prodrug

  2019cites this paper
• Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

  2019cites this paper
• Oral pemetrexed facilitates low‐dose metronomic therapy and enhances antitumor efficacy in lung cancer

  2018cites this paper